Q-omics provides the consensus-scored MIR3945HG profile across patient tissues and cancer cell-line models. MIR3945HG expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR3945HG is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, MIR3945HG RNA expression shows 14,875 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where MIR3945HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3945HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3945HG survival associations across molecular data types. MIR3945HG RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3945HG RNA expression–survival associations across cancer types. High MIR3945HG expression shows unfavorable associations in KIRC, THYM, LGG and LUSC, but favorable associations in SKCM and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR3945HG RNA expression.
This table summarizes MIR3945HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3945HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3945HG shows lower tumor expression in LUAD and LUSC and higher tumor expression in COAD, KIRC, HNSC and STAD. The LUAD box plot shows higher MIR3945HG RNA expression in normal versus tumor tissue (log2 FC = −2.529, t-test p < 0.001).
This table shows molecular features associated with MIR3945HG in patient tissues and cancer cell lines. In patient samples, MIR3945HG shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
